)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Essex Bio-Technology
Essex Bio-Technology (1061) investor relations material
Essex Bio-Technology H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary5 Aug, 2026
Executive summary
Revenue for the six months ended 30 June 2026 was HK$784.7 million, down 10.5% year-over-year, mainly due to regulatory changes and increased VAT in the PRC that could not be passed to customers.
Net profit declined 32.2% to HK$110.7 million, impacted by lower gross margins and reduced exchange gains.
The Group’s core business remains in ophthalmology and surgical biologics, with flagship products accounting for 78.2% of turnover.
Significant investments continue in R&D, particularly in late-stage ophthalmic products and biologics.
Financial highlights
Gross profit margin decreased to 83.6% from 88.8% year-over-year.
Net profit margin fell to 14.1% from 18.6% year-over-year.
Basic and diluted EPS were HK19.53 cents, down from HK28.82 cents.
Interim dividend declared at HK$0.05 per share (2025: HK$0.07).
Cash and cash equivalents stood at HK$806.6 million as of 30 June 2026.
Outlook and guidance
The Group is adapting to regulatory headwinds in the PRC by focusing on compliance, digital engagement, and innovation.
Continued investment in R&D and expansion into new therapeutic areas such as oncology and neurology.
Construction of a second factory in Zhuhai is nearing completion to support future growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Essex Bio-Technology
- Turnover and profit grew, but new PRC VAT law will impact 2026 margins; R&D and expansion continue.1061
H2 2025 - Revenue and profit grew, R&D investment increased, and interim dividend was raised.1061H1 2025
- Revenue and profit fell amid PRC regulatory changes, but R&D and expansion continue.1061H1 2024
- Net profit up 11.6% to HK$307.2M, with flagship biologics driving performance.1061H2 2024
Next Essex Bio-Technology earnings date
H2 202622 Mar, 2027
Essex Bio-Technology
Next Essex Bio-Technology earnings date
H2 202622 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Essex Bio-Technology Limited is a biopharmaceutical company engaged in the research, development, manufacturing, and marketing of therapeutic products. The company focuses on regenerative medicine and specializes in biopharmaceutical drugs for ophthalmology and wound care. Its product portfolio includes formulations derived from recombinant DNA technology and other biological sources. Essex Bio-Technology Limited conducts its operations through integrated facilities that support clinical research, production, and distribution. The company is headquartered in Hong Kong, China, and its shares are listed on the HKEX.